In clinical trials with Soliris, paroxysmal nocturnal hemoglobinuria (PNH) patients experienced a substantial improvement in PNH-related fatigue independent of changes in their anemia. This improvement was larger than
The study showed Velcade-based therapy with melphalan and prednisone (VMP) achieves superior complete response rates which are significantly durable and may be prolonged with continued therapy after the
Brien Holden, CEO of Institute for Eye Research (IER), said: “Through our collaboration with Advanced Medical Optics, we will work to develop, test and deliver, through product innovation
Exelixis has also discussed the trial design with European regulatory agencies. Exelixis is planning to initiate the Phase III trial of XL184 as a potential treatment for medullary
This trial, which is expected to start in July, 2008 is the second Phase I trial for this product. The first Phase I trial was conducted in India,
The results continue to show that romiplostim increased and sustained platelet counts with extended treatment, and reduced the need for concurrent and rescue immune thrombocytopenic purpura (ITP) medications.
In the trial, the currently marketed Azilect 1mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance.
The agreement is subject to certain conditions precedent, including approval by competition authorities in Satisloh’s main host countries. The acquisition could be completed in the second half of
Under the extended agreement, which now runs until June 2010, MorphoSys continues to grant OncoMed access to its proprietary antibody library HuCAL Gold for the use in the
The application seeks approval to initiate Phase I studies on an AMRI compound exclusively licensed to Bristol-Myers Squibb. Upon approval of the clinical trial application by Health Canada,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.